Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

733
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
733
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

245
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
245
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

2.1K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
2.1K
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

479
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
479
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

818
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
818
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

437
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
437

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accurate Protein-Protein Interaction Prediction: Based on Multiview Heterogeneous Graph Autoencoders and Random Masking.

IEEE transactions on neural networks and learning systems·2025
Same author

Pre-trained language models for protein and molecular design.

Physical chemistry chemical physics : PCCP·2025
Same author

Multi-objective drug design with a scaffold-aware variational autoencoder.

Chemical science·2025
Same author

A framework reforming personalized Internet of Things by federated meta-learning.

Nature communications·2025
Same author

Meta-MolNet: A Cross-Domain Benchmark for Few Examples Drug Discovery.

IEEE transactions on neural networks and learning systems·2025
Same author

Dual modality feature fused neural network integrating binding site information for drug target affinity prediction.

NPJ digital medicine·2025

Related Experiment Video

Updated: May 6, 2026

Assays for the Degradation of Misfolded Proteins in Cells
10:56

Assays for the Degradation of Misfolded Proteins in Cells

Published on: August 28, 2016

11.7K

May disordered protein cause serious drug side effect?

Weng Ieong Tou1, Calvin Yu-Chian Chen2

  • 1School of Medicine, College of Medicine, China Medical University, Taichung, 40402, Taiwan.

Drug Discovery Today
|November 5, 2013
PubMed
Summary

Insomnia drug failures may stem from protein architecture. Targeting structurally disordered regions in sleep-related proteins could lead to safer, more effective insomnia treatments.

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

748
Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

7.9K

Related Experiment Videos

Last Updated: May 6, 2026

Assays for the Degradation of Misfolded Proteins in Cells
10:56

Assays for the Degradation of Misfolded Proteins in Cells

Published on: August 28, 2016

11.7K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

748
Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

7.9K

Area of Science:

  • Neuroscience
  • Structural Biology
  • Pharmacology

Background:

  • Insomnia is a sleep disorder causing daytime impairment.
  • Current insomnia drugs have significant side effects.
  • Existing drug targets for insomnia lack sufficient efficacy.

Purpose of the Study:

  • To investigate the structural properties of sleep-related proteins.
  • To explore potential drug designs for reduced side effects.
  • To understand the link between protein architecture and drug failure in insomnia.

Main Methods:

  • Computational prediction of protein structures.
  • Analysis of disordered regions in key sleep-related proteins.
  • Review of existing insomnia drug targets and their mechanisms.

Main Results:

  • A significant portion (>30%) of key sleep proteins (CLOCK, PER1/2/3, BMAL-1, muscarinic acetylcholine receptor-M1, melatonin receptor, casein kinase I) are structurally disordered.
  • Structurally disordered properties are common among these sleep-related proteins.
  • Protein architecture is implicated in the failure of current insomnia medications.

Conclusions:

  • The structural disorder in sleep-related proteins may explain insomnia drug ineffectiveness.
  • Future insomnia drug design should consider these disordered properties.
  • Targeting protein architecture offers a novel strategy for developing safer insomnia therapeutics.